Search
Vidarabine
go.drugbank.com/drugs/DB00194ApprovedWithdrawnIt has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the
AME-527
go.drugbank.com/drugs/DB05879ExperimentalAME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.
Lobeglitazone
go.drugbank.com/drugs/DB09198InvestigationalLobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. … It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells.
Categories: Drugs Used in DiabetesPramiracetam
go.drugbank.com/drugs/DB13247ApprovedPramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470]. … It was also previously approved in the United States with orphan drug designation [L1469].
Levomethadone
go.drugbank.com/drugs/DB13515InvestigationalCategories: Drugs Used in Opioid Dependence, Drugs Used in Addictive DisordersTesmilifene
go.drugbank.com/drugs/DB04905InvestigationalTesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast
Synonyms: N,N-diethyl-2-((4-phenylmethyl)phenoxy)ethanamineProgabide
go.drugbank.com/drugs/DB00837ExperimentalProgabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. … In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated
MN-246
go.drugbank.com/drugs/DB05981ExperimentalMN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.
MPI-674
go.drugbank.com/drugs/DB05749ExperimentalMPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.